‘A vaccine with 50 per cent effectiveness’: Astrazeneca releases 111-page Covid-19 vaccine trial blueprint | All you need to knowworldUpdated: Sep 20, 2020 18:52 ISTPharma company Astrazeneca has released a 111-page trial blueprint, after several questions were raised about its Covid-19 vaccine trials since two participants in the UK reported illness. Controversy over Oxford-Astrazeneca vaccineOn September 8, Astrazeneca confirmed that it has stopped trials on September 6 after two participants reported illness. After the UK authorities announced that the illness reported was not related to the vaccine shot, Astrazeneca resumed its trial. However, the United States has not yet permitted the resumption of Oxford vaccine trial. What we know so far about illness reportedly prompted by Astrazeneca vaccine shots?

Source: Hindustan Times September 20, 2020 13:21 UTC